Twitter Beğeni Hilesi

Looking forward to having a nice "conversation" with Dr. Liz Brem tomorrow! 😀 Join us is you are in LA #CART #Lymphona Fred Hutchinson Cancer Center

Excited to share our paper in Nature Biotechnology. We've developed a CAR-Enhancer (CAR-E) that enhances the activity and persistence of CAR T-cells. These memory CAR T-cells can re-expand months later. Here's a brief summary: go.nature.com/3SuUgj3

BREAKING: The #FDA has granted afami-cel, an engineered T-cell receptor therapy which works to target the MAGE-A4 protein, an accelerated approval for the treatment of patients with advanced synovial sarcoma. targetedonc.com/view/fda-appro…

Imagine winning a gold medal at the Olympics then next week you’re on rounds with a nephrologist answering questions about free water deficit

Starting the second #SeattleCellTherapySummit Binaytara Foundation with my co-chair Krish Patel . Looking forward to 2 days of great presentations and discussion with our outstanding speakers and attendees. education.binayfoundation.org/content/2024-s… Fred Hutchinson Cancer Center

Dr. Fong from Fred Hutchinson Cancer Center talking about future directions in immunotherapy for solid tumors. #SeattleCellTherapySummit Binaytara Foundation

Exciting to hear more about TCR therapies for synovial sarcomas from Dr. Elizabeth Loggers at our Seattle Cellular Therapy Summit! Focus on the SPEARHEAD-1 trial that led to the recent FDA approval of the MAGE-A4-directed product afamistresgene for metastatic synovial sarcoma.

Exciting to see the increasing role of immunotherapy in solid tumors #SeattleCellTherapySummit Binaytara Foundation Fred Hutchinson Cancer Center

Outstanding talk on access barriers to CART by Dr. Marc Hoffman University of Kansas. Binaytara Foundation #SeattleCellTherapySummit

Day 2 of #SeattleCellTherapySummit . Starting with myeloma debates Dr. Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 reviewing the CART data. Binaytara Foundation

Dr. Rahul Banerjee, MD, FACP from Fred Hutchinson Cancer Center arguing for NOT using CART in second line for #mmsm #SeattleCellTherapySummit Binaytara Foundation

Debate: should anti-CD19 Abs be used before CD19 CARs? Mehdi Hamadani, MD : yes Matt Lunning D.O. : no What do you think? #SeattleCellTherapySummit Binaytara Foundation

Masterclass with Prof. Mehdi Hamadani, MD on a very controversial topic: are CD19-targeted therapies prior to CD19 CAR T-cell therapy ever a good idea? #SCTS24 Binaytara Foundation

Timely update from Dr. Matthew Frank Stanford Medicine Excited to see the next steps for CD22 CAR T-cell therapy in the pivotal CARGO Therapeutics study, and beyond LBCL! Binaytara Foundation

Which immunotherapy modality is better /most promising for first line #DLBCL? Dr. Neelapu: #CART Dr. Lynch (Ryan Lynch ) : bispecific abs #SeattleCellTherapySummit Binaytara Foundation Fred Hutchinson Cancer Center

CART therapy for T-cell Lymphoma. A great talk by Dr. Rayne Rouce Texas Children's . #SeattleCellTherapySummit Binaytara Foundation

Omg, our paper was selected for the Nature Immunology cover with the amazing "Black Hole Thymus" illustration by DrawImpacts

My second book “THE CANCER JOURNEY” launches 9/24/24 & is available to pre-order a.co/d/f0mwZCZ I leverage storytelling to explain & simplify everything related to cancer from A-Z; written in an easy to read & understand language so it reaches everyone. Check it out.

Fred Hutch finalized an agreement to acquire 1165 Eastlake Avenue East and enter into a joint venture partnership for a 70% interest in 1201 and 1208 Eastlake Avenue East that will add more than 300,000 square feet to its South Lake Union campus. Read more bit.ly/4d2hOTF